Abstract

Niacin inhibits fatty acid flux from adipose tissue to liver, reduces hepatic triglyceride synthesis and increases hepatic lipid oxidation. Thus, niacin may have a role in the regulation of liver fat content in humans. We tested if dietary intake of niacin predicts change of liver fat content during a lifestyle intervention. To this end, we estimated the composition of diet from diaries of 202 healthy subjects at risk of type 2 diabetes undergoing lifestyle intervention comprising physical activity and diet counselling. Total-, subcutaneous- and visceral adipose tissue mass were measured by magnetic resonance (MR) tomography and liver fat content by 1H-MR spectroscopy at baseline and after 9 months of follow-up. Among fat compartments, liver fat content showed the largest decrease (−32%, p < 0.0001). High baseline niacin intake predicted a larger decrease of liver fat (p = 0.004). Subjects in the highest quartile of niacin intake at baseline also had the largest decrease of liver fat (1st:−10%; 2nd:−27%; 3rd:−35%; 4th:−37%). Among 58 subjects with nonalcoholic fatty liver disease (NAFLD) at baseline, NAFLD resolved in 23 subjects during the lifestyle intervention. For one standard deviation increase in niacin intake, the odds ratio for resolution of NAFLD was 1.77 (95% CI, 1.00–3.43). High dietary niacin intake may have a favorable effect on the reduction of liver fat during lifestyle intervention.

Details

Title
Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention
Author
Linder Katarzyna 1 ; Willmann, Caroline 2 ; Kantartzis Konstantinos 1   VIAFID ORCID Logo  ; Machann Jürgen 3 ; Schick, Fritz 3 ; Graf Marjo 4 ; Kümmerle Sabine 4 ; Hans-Ulrich, Häring 1 ; Fritsche, Andreas 1 ; Stefan, Norbert 1 ; Wagner, Róbert 1   VIAFID ORCID Logo 

 University Hospital of Tübingen, Department of Internal Medicine IV, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249); Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Zentrum München at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); Deutsches Zentrum für Diabetesforschung, Neuherberg, Germany (GRID:grid.452622.5) 
 University Hospital of Tübingen, Department of Internal Medicine IV, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249); Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Zentrum München at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) 
 Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Zentrum München at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); Deutsches Zentrum für Diabetesforschung, Neuherberg, Germany (GRID:grid.452622.5); University Hospital of Tübingen, Section on Experimental Radiology, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249) 
 University Hospital of Tübingen, Department of Internal Medicine IV, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249) 
Publication year
2019
Publication date
Feb 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2350325040
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.